Management of Hepatitis B in Pregnancy (original) (raw)

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016–2021: actions for impact. World Health Organization; 2021.
    Google Scholar
  2. World Health Organization. Global Hepatitis Report 2017. World Health Organization; Report No.: Licence: CC BY-NC-SA 3.0 IGO.
  3. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20:607–28.
    Article PubMed PubMed Central Google Scholar
  4. Kushner T, Chen Z, Tressler S, Kaufman H, Feinberg J, Terrault NA. Trends in hepatitis B infection and immunity among women of childbearing age in the United States. Clin Infect Dis. 2020;71:586–92.
    Article PubMed Google Scholar
  5. World Health Organization. Prevention of mother-to-child transmission of Hepatitis B Virus: guidelines on antiviral prophylaxis in pregnancy. 2020. Retrieved from https://www.who.int/publications/i/item/978-92-4-000270-8.
  6. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977;105:94–8.
    Article CAS PubMed Google Scholar
  7. Veronese P, Dodi I, Esposito S, Indolfi G. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol. 2021;27:4182–93.
    Article CAS PubMed PubMed Central Google Scholar
  8. World Health Organization. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15. World Health Organization; 2015.
    Google Scholar
  9. Pépin J, Abou Chakra CN, Pépin E, Nault V. Evolution of the global use of unsafe medical injections, 2000-2010. PLoS One. 2013;8:e80948.
    Article PubMed PubMed Central Google Scholar
  10. World Health Organization. Global health sector strategy on viral Hepatitis 2016-2021. Towards ending viral hepatitis. 2016. Retrieved from https://www.who.int/publications/i/item/WHO-HIV-2016.06.
  11. Chen B, Wang Y, Lange M, Kushner T. Hepatitis C is associated with more adverse pregnancy outcomes than hepatitis B: a 7-year national inpatient sample study. Hepatol Commun. 2022;6:2465–73.
    Article PubMed PubMed Central Google Scholar
  12. Huang Q-T, Wei S-S, Zhong M, Hang L-L, Xu Y-Y, Cai G-X, et al. Chronic hepatitis B infection and risk of preterm labor: a meta-analysis of observational studies. J Clin Virol. 2014;61:3–8.
    Article PubMed Google Scholar
  13. Zhang Y, Chen J, Liao T, Chen S, Yan J, Lin X. Correction to: Maternal HBsAg carriers and pregnancy outcomes: a retrospective cohort analysis of 85,190 pregnancies. BMC Pregnancy Childbirth. 2021;21:131.
    Article PubMed PubMed Central Google Scholar
  14. Jiang R, Wang T, Yao Y, Zhou F, Huang X. Hepatitis B infection and intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis. Medicine. 2020;99:e21416.
    Article PubMed PubMed Central Google Scholar
  15. Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol. 2005;43:771–5.
    Article CAS PubMed Google Scholar
  16. Sirilert S, Traisrisilp K, Sirivatanapa P, Tongsong T. Pregnancy outcomes among chronic carriers of hepatitis B virus. Int J Gynaecol Obstet. 2014;126:106–10.
    Article PubMed Google Scholar
  17. Cui A-M, Cheng X-Y, Shao J-G, Li H-B, Wang X-L, Shen Y, et al. Maternal hepatitis B virus carrier status and pregnancy outcomes: a prospective cohort study. BMC Pregnancy Childbirth. 2016;16:87.
    Article PubMed PubMed Central Google Scholar
  18. Kong D, Liu H, Wei S, Wang Y, Hu A, Han W, et al. A meta-analysis of the association between gestational diabetes mellitus and chronic hepatitis B infection during pregnancy. BMC Res Notes. 2014;7:139.
    Article PubMed PubMed Central Google Scholar
  19. Huang QT, Chen JH, Zhong M, Xu YY, Cai CX, Wei SS, et al. The risk of placental abruption and placenta previa in pregnant women with chronic hepatitis B viral infection: a systematic review and meta-analysis. Placenta. 2014;35:539–45.
    Article CAS PubMed Google Scholar
  20. Kushner T, Shaw PA, Kalra A, Magaldi L, Monpara P, Bedi G, et al. Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: a regional hospital-based cohort study. Liver Int. 2018;38:813–20.
    Article CAS PubMed Google Scholar
  21. Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau D, et al. Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B. Am J Gastroenterol. 2016;111:1410–5.
    Article CAS PubMed Google Scholar
  22. ter Borg MJ, Leemans WF, de Man RA, Janssen HLA. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15:37–41.
    Article PubMed Google Scholar
  23. Giles M, Visvanathan K, Lewin S, Bowden S, Locarnini S, Spelman T, et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut. 2015;64:1810–5.
    Article CAS PubMed Google Scholar
  24. Liu J, Wang J, Qi C, Cao F, Tian Z, Guo D, et al. Baseline hepatitis B virus titer predicts initial postpartum hepatic flare: a multicenter prospective study. J Clin Gastroenterol. 2018;52:902–7.
    Article PubMed Google Scholar
  25. Nguyen V, Tan PK, Greenup A-J, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39:1225–34.
    Article CAS PubMed Google Scholar
  26. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019;322:349–54.
    Article Google Scholar
  27. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.
    Article PubMed Google Scholar
  28. Dionne-Odom J, Tita ATN, Silverman NS. #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol. 2016;214:6–14.
    Article PubMed Google Scholar
  29. Han Z, Zhang Y, Zhou J, Wang Q, Huang Y, Hou H. Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases. BMC Infect Dis. 2021;21:716.
    Article CAS PubMed PubMed Central Google Scholar
  30. Han Z, Zhang Y, Bai X, Yin Y, Xu C, Hou H. Mother-to-child transmission of hepatitis B virus after amniocentesis: a retrospective matched cohort study. Prenat Diagn. 2019;39:431–40.
    Article CAS PubMed Google Scholar
  31. Du X, Zhang L, Liu Z, Qian Y, Zhang X, Hu T, et al. Risk of mother-to-child transmission after amniocentesis in pregnant women with hepatitis B virus: a retrospective cohort study. Am J Obstet Gynecol. 2024;230:249.e1–8.
    Article PubMed Google Scholar
  32. Kushner T, Sarkar M. Chronic hepatitis B in pregnancy. Clin Liver Dis. 2018;12:24–8.
    Article Google Scholar
  33. Core concepts - preventing HBV perinatal transmission - prevention of HBV - hepatitis B online. Internet, Available from https://www.hepatitisb.uw.edu/go/prevention-hbv/preventing-perinatal-transmission-hbv/core-concept/all Cited 2023 Aug 10.
  34. Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, et al. Universal hepatitis B vaccination in adults aged 19-59 years: updated recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:477–83.
    Article PubMed PubMed Central Google Scholar
  35. Gupta I, Ratho RK. Immunogenicity and safety of two schedules of Hepatitis B vaccination during pregnancy. J Obstet Gynaecol Res. 2003;29:84–6.
    Article PubMed Google Scholar
  36. Pregnancy guidelines and recommendations by vaccine [Internet]. 2023. Available from: https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guidelines.html cited 2023 Aug 18.
  37. Kushner T, Huang V, Janssen R. Safety and immunogenicity of HepB-CpG in women with documented pregnancies post-vaccination: a retrospective chart review. Vaccine. 2022;40:2899–903.
    Article CAS PubMed Google Scholar
  38. World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus (HBV): guidelines on antiviral prophylaxis in pregnancy. World Health Organization; 2020.
    Google Scholar
  39. Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, et al. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2019;17:1929–36.e1.
    Article PubMed Google Scholar
  40. Rajbhandari R, Chung RT. Treatment of hepatitis B: a concise review. Clin Transl Gastroenterol. 2016;7:e190.
    Article PubMed PubMed Central Google Scholar
  41. Wong GL-H. Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. Clin Mol Hepatol. 2018;24:108–13.
    Article PubMed PubMed Central Google Scholar
  42. Pan CQ, Duan Z-P, Bhamidimarri KR, Zou H-B, Liang X-F, Li J, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol. 2012;10:452–9.
    Article PubMed Google Scholar
  43. Nayagam S, de Villiers MJ, Shimakawa Y, Lemoine M, Thursz MR, Walsh N, et al. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study. Lancet Gastroenterol Hepatol. 2023;8:635–45. Important modeling study highlighting the potential impact of universal peripartum prophylaxis and describing current barriers to implementation.
    Article PubMed Google Scholar
  44. Lee YS, Bang SM, Lee Y-S. Benefits and risks of antiviral treatment during pregnancy in patients with chronic hepatitis B. J Clin Med Res. 2021:10. [Internet]. Available from: https://doi.org/10.3390/jcm10112320.
  45. Di Perri G. Tenofovir alafenamide (TAF) clinical pharmacology. Infez Med. 2021;29:526–9.
    CAS PubMed PubMed Central Google Scholar
  46. Gao F, Zhang W-T, Lin Y-Y, Wang W-M, Xu N, Bai G-Q. Early start of tenofovir treatment achieves better viral suppression in pregnant women with a high HBV viral load: a real-world prospective study. Infect Drug Resist. 2019;12:3475–84.
    Article CAS PubMed PubMed Central Google Scholar
  47. Wu Y, Liu J, Feng Y, Fu S, Ji F, Ge L, et al. Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis. Hepatol Int. 2020;14:180–9.
    Article PubMed Google Scholar
  48. Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, et al. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411–29.
    Article PubMed PubMed Central Google Scholar
  49. Li M, Sun F, Bi X, Lin Y, Yang L, Jiang T, et al. Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection. Hepatol Int. 2023;17:42–51.
    Article PubMed Google Scholar
  50. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, Neitzel SM, Ward JW. Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1–20.
  51. Mast EE, Weinbaum CM, Fiore AE, Alter MJ, Bell BP, Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55:1–33. quiz CE1–4.
    PubMed Google Scholar
  52. Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, et al. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial. Lancet Infect Dis. 2022;22:1181–90. Important phase 4 trial that focuses on prevention of vertical transmission of HBV without HBIg, which has important implications in developing countries that do not have access to HBIg.
    Article CAS PubMed Google Scholar
  53. Liang LY, Wong GL-H. Unmet need in chronic hepatitis B management. Clin Mol Hepatol. 2019;25:172–80.
    Article PubMed PubMed Central Google Scholar
  54. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374:2324–34.
    Article CAS PubMed Google Scholar
  55. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014; [Internet]. Available from: https://doi.org/10.1002/hep.27034.
  56. Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis. 2015;61:996–1003.
    Article CAS PubMed PubMed Central Google Scholar
  57. Jacobson DL, Patel K, Williams PL, Geffner ME, Siberry GK, DiMeglio LA, et al. Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation. Pediatr Infect Dis J. 2017;36:189–97.
    Article PubMed PubMed Central Google Scholar
  58. Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19:817.
    Article PubMed PubMed Central Google Scholar
  59. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496–505.
    Article CAS PubMed Google Scholar
  60. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
    PubMed PubMed Central Google Scholar
  61. Baltrusaitis K, Makanani B, Tierney C, Fowler MG, Moodley D, Theron G, et al. Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial. BMC Infect Dis. 2022;22:634.
    Article CAS PubMed PubMed Central Google Scholar
  62. Li Z, Xie B, Yi N, Cai H, Yi W, Gao X. Efficacy and safety of tenofovir disoproxil fumarate or telbivudine used throughout pregnancy for the prevention of mother-to-child transmission of hepatitis B virus: a cohort study. Eur J Obstet Gynecol Reprod Biol. 2022;276:102–6.
    Article CAS PubMed Google Scholar
  63. Wang M, Ran R, Zhu Y, Zhang H. Comparison of tenofovir disoproxil fumarate and telbivudine in preventing hepatitis B transmission in mothers with high viral load. Int J Gynaecol Obstet. 2023;160:646–52. Important prospective cohort study demonstrating TDF’s ability to more effectively reduce viral load and have fewer liver abnormalities compared to telbivudine.
    Article CAS PubMed Google Scholar
  64. Han G, Zhou G, Sun T, Luo X, Xu J, Chen C, et al. Tenofovir alafenamide in blocking mother-to-child transmission of hepatitis B virus: a multi-center, prospective study. J Matern Fetal Neonatal Med. 2022;35:10551–8.
    Article CAS PubMed Google Scholar
  65. Zeng Q-L, Zhang H-X, Zhang J-Y, Huang S, Li W-Z, Li G-M, et al. Tenofovir alafenamide for pregnant Chinese women with active chronic hepatitis B: a multicenter prospective study. Clin Gastroenterol Hepatol. 2022;20:2826–37.e9. Important prospective cohort study on pregnant women with CHB showing similar effectiveness and safety with TAF therapy compared to TDF.
    Article CAS PubMed Google Scholar
  66. Thimm MA, Livingston A, Ramroop R, Eke AC. Pregnancy outcomes in pregnant women with HIV on tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF). J AIDS HIV Treat. 2022;4:6–13.
    PubMed PubMed Central Google Scholar
  67. Zeng Q-L, Yu Z-J, Ji F, Li G-M, Zhang G-F, Xu J-H, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective, observational study. Clin Infect Dis. 2021;73:e3324–32.
    Article CAS PubMed Google Scholar
  68. Li B, Liu Z, Liu X, Liu D, Duan M, Gu Y, et al. Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load. Hepatol Int. 2021;15:1103–8.
    Article PubMed Google Scholar
  69. Hepatitis: preventing mother-to-child transmission of the hepatitis B virus [Internet]. Available from: https://www.who.int/news-room/questions-and-answers/item/hepatitis-preventing-mother-to-child-transmission-of-the-hepatitis-b-virus cited 2023 Aug 9.
  70. Hepatitis B. [Internet], Available from: http://www.who.int/mediacentre/factsheets/fs204/en/ cited 2023 Aug 9.
  71. Hepatitis B vaccination of infants - adolescents. 2021. [Internet], Available from: http://www.cdc.gov/hepatitis/hbv/vaccchildren.htm cited 2023 Aug 9.
  72. Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME. Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg− mothers: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;70:396–404.
    Article PubMed Google Scholar
  73. Lu Y, Liang X-F, Wang F-Z, Yan L, Li R-C, Li Y-P, et al. Hepatitis B vaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg (+)/HBeAg (-) mothers. Vaccine. 2017;35:40–5.
    Article CAS PubMed Google Scholar
  74. Peng S, Wan Z, Liu T, Li X, Du Y. Cesarean section reduces the risk of early mother-to-child transmission of hepatitis B virus. Dig Liver Dis. 2018;50:1076–80.
    Article PubMed Google Scholar
  75. Deng TK, Yang P, Liu X, Wang D, Luo H, Zhou J, et al. Influence of different delivery modes and HBV DNA titers on mother-to-child transmission of hepatitis B. Clin Res Hepatol Gastroenterol. 2021;45:101542.
    Article CAS PubMed Google Scholar
  76. Yang M, Qin Q, Fang Q, Jiang L, Nie S. Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: a meta-analysis. BMC Pregnancy Childbirth. 2017;17:303.
    Article PubMed PubMed Central Google Scholar
  77. Chen HL, Cai JY, Song YP, Zha ML, Qin G. Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: a systematic review and a meta-analysis. Midwifery. 2019;74:116–125. https://doi.org/10.1016/j.midw.2019.03.024.
  78. Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011;165:837–46.
    Article PubMed Google Scholar
  79. Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002;99:1049–52.
    PubMed Google Scholar
  80. Benaboud S, Pruvost A, Coffie PA, Ekouévi DK, Urien S, Arrivé E, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother. 2011;55:1315–7.
    Article CAS PubMed Google Scholar
  81. Mirochnick M, Taha T, Kreitchmann R, Nielsen-Saines K, Kumwenda N, Joao E, et al. Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr. 2014;65:33–41.
    Article CAS PubMed PubMed Central Google Scholar
  82. Waitt C, Olagunju A, Nakalema S, Kyohaire I, Owen A, Lamorde M, et al. Plasma and breast milk pharmacokinetics of emtricitabine, tenofovir and lamivudine using dried blood and breast milk spots in nursing African mother-infant pairs. J Antimicrob Chemother. 2018;73:1013–9.
    Article CAS PubMed PubMed Central Google Scholar
  83. Van Rompay KKA, Hamilton M, Kearney B, Bischofberger N. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother. 2005;49:2093–4.
    Article PubMed PubMed Central Google Scholar
  84. Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL. Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis. 2015;60:275–8.
    Article CAS PubMed Google Scholar
  85. Liu Z, Chen Z, Cui F, Ding Y, Gao Y, Han G, et al. Management algorithm for prevention of mother-to-child transmission of hepatitis B virus (2022). J Clin Transl Hepatol. 2022;10:1004–10.
    Article PubMed PubMed Central Google Scholar
  86. Erturk US, Mete B, Ozaras R, Saltoglu N, Balkan II, Mert A, et al. Plasma and breast milk pharmacokinetics of tenofovir disoproxil fumarate in nursing mother with chronic hepatitis B-infant pairs. Antimicrob Agents Chemother. 2021;65:e0111021. This paper examines the distribution of TDF in both plasma and breast milk, and provides new evidence for the safety of infants exposed to breast milk containing TDF.
    Article CAS PubMed Google Scholar

Download references